PIRS Palvella Therapeutics Inc.


$ 74.52 $ 0.01 (0.01 %)    

Friday, 17-Oct-2025 18:44:07 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ na
$ 72.17
$ 73.15 x 1
$ 74.53 x 3
$ 70.98 - $ 74.39
$ 11.17 - $ 77.67
103,118
na
na
$ -0.33
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 palvella-therapeutics-announces-first-patient-dosed-in-selva-phase-3-clinical-trial-of-qtorin-39-rapamycin-anhydrous-gel-for-the-treatment-of-microcystic-lymphatic-malformations

Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treat...

 palvella-therapeutics-and-pieris-pharmaceuticals-to-merge-creating-a-nasdaq-listed-entity-with-805m-cash-to-drive-development-of-novel-skin-disease-therapies

Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing...

 pieris-pharmaceuticals-announces-1-for-80-reverse-stock-split

https://www.sec.gov/Archives/edgar/data/1583648/000143774924012442/ex_655549.htm

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION